US2003187240A1PendingUtilityA1

2' -modified oligonucleotides

Assignee: ISIS PHARMACEUTICALS INCPriority: Jan 11, 1990Filed: Jan 28, 2003Published: Oct 2, 2003
Est. expiryJan 11, 2010(expired)· nominal 20-yr term from priority
C12N 2310/3533C12Y 113/11012C12N 2310/321C07H 19/20C12N 15/113C07H 19/06C07H 23/00C07H 19/10C12N 15/111C12N 2310/3531C07H 19/16C07H 21/04C07H 21/00C12N 2310/315C12N 2310/322C12N 2310/11C12N 2310/333C12N 2310/3523C12N 2310/3521C12N 9/0069C12N 2310/33C12N 2310/3125C12N 15/1137C12N 2310/32C07H 19/04C12Q 1/68C07J 43/003A61K 48/00A61K 38/00C12N 2310/336A61K 31/7125C12N 2310/3527
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the 2′-deoxyfuranosyl moieties of the nucleoside unit is modified. Treatment of diseases caused by various viruses and other causative agents is provided.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A compound comprising a plurality of covalently-bound nucleosides that individually include a ribose or deoxyribose sugar portion and a base portion, wherein: 
 said nucleosides are joined together by internucleoside linkages such that the base portion of said nucleosides form a mixed base sequence;    at least one of said nucleosides includes a modified ribofuranosyl moiety bearing a 2′-fluoro substituent;    provided that at least two of said nucleosides are 2-fluoro modified ribofuranosyl nucleosides when said internucleoside linkages are phosphodiester linkages.    
     
     
         2 . The compound of  claim 1  having 5 to 50 nucleoside linked nucleosides.  
     
     
         3 . The compound of  claim 1  wherein at least two of said nucleosides are covalently bound through phosphorothioate, methyl phosphoate, or phosphate alkylate internucleoside linkages.

Join the waitlist — get patent alerts

Track US2003187240A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.